ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
澳股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
RECCE PHARMACEUTICALS LTD
0.375
+0.005
1.35%
成交量:
3.88万
成交额:
1.45万
市值:
1.15亿
市盈率:
-3.31
高:
0.375
开:
0.370
低:
0.367
收:
0.370
52周最高:
0.730
52周最低:
0.347
股本:
3.06亿
流通股本:
1.69亿
量比:
0.60
换手率:
0.02%
股息:
- -
股息率:
- -
每股收益(TTM):
-0.113
每股收益(LYR):
-0.090
净资产收益率:
-1277.62%
总资产收益率:
-581.01%
市净率:
-6.15
市盈率(LYR):
-4.15
数据加载中...
总览
公司
新闻资讯
公告
Recce Pharmaceuticals Ltd 研发新型合成抗感染药物 直击耐药超级细菌
美股速递
·
07/30
Recce Pharmaceuticals称HREC批准加速其全球III期DFI战略
投资观察
·
06/22
Recce Pharmaceuticals Ltd 获许可方于沙特、海合会、埃及、阿尔及利亚及摩洛哥获得R327g独家权利
美股速递
·
05/27
Recce Pharmaceuticals Ltd 将获净售价30%分成及超5000万美元年销售额6%特许权使用费
美股速递
·
05/27
RECCE PHARMACEUTICALS LTD签署十年独家协议,含预付款及最高350万美元里程碑付款
美股速递
·
05/27
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/RCE.AU/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.375,"timestamp":1787638320000,"preClose":0.37,"halted":0,"volume":38796,"delay":0,"changeRate":0.013513513513513526,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":305520100,"eps":-0.113284,"marketStatus":"已收盘","change":0.005,"latestTime":"08-25 16:12:00 AEST","open":0.37,"high":0.375,"low":0.367,"amount":14492,"amplitude":0.021622,"askPrice":0.385,"askSize":35899,"bidPrice":0.375,"bidSize":13044,"shortable":3,"etf":0,"ttmEps":-0.113284,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.37,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.59937,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCE.AU","preClose":0.37,"auctionPrice":0.37,"auctionVolume":6,"auctionTime":1787637622340,"referencePrice":0.375,"referenceTime":1787653803093,"auction":3,"marketStatus":"盘后竞价","timestamp":1787637622340}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-581.01%","roe":"-1277.62%","lyrEps":-0.090423,"volumeRatio":0.59937,"shares":305520100,"dividePrice":0,"high":0.375,"amplitude":0.021622,"preClose":0.37,"low":0.367,"week52Low":0.347,"pbRate":"-6.15","psRate":"117.56","week52High":0.73,"institutionHeld":0,"latestPrice":0.375,"committee":-0.466972,"eps":-0.113284,"divideRate":0,"volume":38796,"delay":0,"ttmEps":-0.113284,"open":0.37,"prevYearClose":0.65,"prevWeekClose":0.365,"prevMonthClose":0.37,"prevQuarterClose":0.405,"fiveDayClose":0.38,"twentyDayClose":0.365,"sixtyDayClose":0.545,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1195921803","title":"Recce Pharmaceuticals Ltd 研发新型合成抗感染药物 直击耐药超级细菌","url":"https://stock-news.laohu8.com/highlight/detail?id=1195921803","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195921803?lang=zh_cn&edition=fundamental","pubTime":"2026-07-30 08:40","pubTimestamp":1785372009,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd(简称RCE)正致力于开发一种全新类型的合成抗感染药物。这些药物旨在应对那些对现有抗生素产生耐药性的超级细菌,直击当前全球公共卫生领域的重大威胁。通过设计独特的合成分子,该公司力求在耐药性问题上实现突破,为日趋严峻的感染治疗困境提供新方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110230784","title":"Recce Pharmaceuticals称HREC批准加速其全球III期DFI战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1110230784","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110230784?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 09:35","pubTimestamp":1782092148,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd宣布,其人类研究伦理委员会的批准将加速公司在全球范围内实施针对糖尿病足感染的III期临床试验战略。这一进展标志着公司在该关键治疗领域迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139423312","title":"Recce Pharmaceuticals Ltd 获许可方于沙特、海合会、埃及、阿尔及利亚及摩洛哥获得R327g独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1139423312","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139423312?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839482,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd 宣布,其许可合作方已获得在沙特阿拉伯、海湾合作委员会国家、埃及、阿尔及利亚及摩洛哥市场开发与商业化新型抗菌候选药物R327g的独家权利。此项授权协议的达成,标志着该公司在中东与北非关键市场的战略布局取得重要进展,有望进一步拓展其核心产品的全球覆盖范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198655607","title":"Recce Pharmaceuticals Ltd 将获净售价30%分成及超5000万美元年销售额6%特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1198655607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198655607?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839475,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd 已达成一项关键商业协议。根据协议条款,该公司将有权获得其产品销售净售价的30%作为分成。此外,当年销售额超过5000万美元时,Recce还将额外获得超出部分销售额6%的特许权使用费。这一安排为该公司未来的收入流奠定了重要基础,并与其核心产品的商业化前景紧密相连。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110626672","title":"RECCE PHARMACEUTICALS LTD签署十年独家协议,含预付款及最高350万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1110626672","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110626672?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839474,"startTime":"0","endTime":"0","summary":"RECCE PHARMACEUTICALS LTD宣布达成一项为期十年的独家合作协议。根据协议条款,公司将获得一笔预付款,并有资格在达成特定研发里程碑后,获得总额最高达350万美元的额外付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}